Summary

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published: February 16, 2024
doi:

Summary

Here, we established in vivo osteo-organoids triggered by bone morphogenetic protein-2-loaded gelatin scaffolds to harvest therapeutic hematopoietic stem/progenitor cells for the reconstruction of a damaged hematopoietic and immune system. Overall, this approach can provide a promising cell source for cell therapies.

Abstract

Hematopoietic stem cell transplantation (HSCT) requires a sufficient number of therapeutic hematopoietic stem/progenitor cells (HSPCs). To identify an adequate source of HSPCs, we developed an in vivo osteo-organoid by implanting scaffolds loaded with recombinant human bone morphogenetic protein-2 (rhBMP-2) into an internal muscle pouch near the femur in mice. After 12 weeks of implantation, we retrieved the in vivo osteo-organoids and conducted flow cytometry analysis on HPSCs, revealing a significant presence of HSPC subsets within the in vivo osteo-organoids.

We then established a sublethal model of hematopoietic/immune system injury in mice through radiation and performed hematopoietic stem cell transplantation (HSCT) by injecting the extracted osteo-organoid-derived cells into the peripheral blood of radiated mice. The effect of hematopoietic recovery was evaluated through hematological, peripheral blood chimerism, and solid organ chimerism analyses. The results confirmed that in vivo osteo-organoid-derived cells can rapidly and efficiently reconstruct damaged peripheral and solid immune organs in irradiated mice. This approach holds potential as an alternative source of HSPCs for HSCT, offering benefits to a larger number of patients.

Introduction

Hematopoietic stem cell transplantation stands as the conventional therapy for a variety of hematological malignancies, as well as numerous inherited and autoimmune disorders1,2,3,4. Nevertheless, the restricted quantity and origin of hematopoietic stem/progenitor cells (HSPCs) have emerged as a substantial impediment to the clinical implementation of hematopoietic stem cell transplantation (HSCT)5,6.

Large-scale in vitro cell expansion is a commonly employed method for harvesting therapeutic cells5,7. Various studies have developed conditions that stimulate HSPCs to self-renew in vitro, typically through the use of a combination of self-renewal agonists (such as cytokines and growth factors) and serum albumin, resulting in the ex vivo expansion of HSPCs8. However, it is important to note that current methods are still time-consuming and challenging to maintain the self-renewal capacity of expanded HSPCs9.

In contrast to the aforementioned method, harvesting cells in vivo presents a new and innovative strategy. This approach involves the establishment of an in vivo osteo-organoid that mimics the native bone marrow structure10,11. To achieve this, we form in vivo osteo-organoids using bone morphogenetic protein-2 (BMP-2)-loaded gelatin scaffolds to obtain abundant and high-quality autologous cell cocktails, including HSPCs. By therapeutically applying these osteo-organoids, we have successfully treated irradiation damage and demonstrated that HSPCs derived from the osteo-organoids can rapidly and stably reconstitute the experimentally impaired immune system.

Protocol

Male and female C57BL/6 mice, aged 8-10 weeks, were included in the study. All mice were housed in the animal facility of East China University of Science and Technology. All the experimental procedures were approved by the Institutional Animal Care and Use Committees of East China University of Science and Technology (ECUST-21010). 1. Fabrication of bioactive scaffold Preparation Put the cleaned and dried surgical scissors and tweezers into a 1,000 mL …

Representative Results

As per the protocol, we have created a bioactive scaffold by dripping BMP-2 into a degradable gelatin sponge under sterile conditions. The scaffold was then implanted into the lower limb muscles of mice to establish in vivo osteo-organoids. After an incubation period of 12 weeks, we conducted macroscopic photography, histological analysis, and flow cytometry analysis on the osteo-organoids (Figure 1A). The gelatin sponge was cut into cubes with dimensions of 5 mm x 5 mm x 5 mm, and …

Discussion

In this protocol, we present an approach to establish in vivo osteo-organoids with bone marrow-like structures by implanting gelatin sponge scaffolds loaded with BMP-2. We demonstrate that these in vivo osteo-organoids can stably produce therapeutic HSPCs over a long period of time (more than 12 weeks). Compared to existing in vitro expansion or in vivo incubation methods that load cells, this protocol can obtain cell cocktails with diverse cell types, including HSPCs and various immun…

Divulgazioni

The authors have nothing to disclose.

Acknowledgements

This research was supported by the Basic Science Center Program (No. T2288102), the Key Program of the National Natural Science Foundation of China (No. 32230059), the National Natural Science Foundation of China (No. 32301123), the Foundation of Frontiers Science Center for Materiobiology and Dynamic Chemistry (No. JKVD1211002), the Wego Project of Chinese Academy of Sciences (No. (2020) 005), the Project of National Facility for Translational Medicine (Shanghai) (No. TMSK-2021-134), and the China Postdoctoral Science Foundation (No. 2022M721147).

Materials

AF700-anti-CD11b (M1/70) eBioscience 56-0112-82 Store at 4 °C. Dilute 1:200 for staining.
AF700-anti-Sca-1 (D7) BioLegend 108141 Store at 4 °C. Dilute 1:200 for staining.
APC-anti-CD3e (145-2C11) Tonbo 20-0031-U100 Store at 4 °C. Dilute 1:200 for staining.
bio-anti-CD34 (RAM34) eBioscience 13-0341-82 Store at 4 °C. Dilute 1:200 for staining.
BV421-anti-CD127 (IL-7Rα) BioLegend 135023 Store at 4 °C. Dilute 1:200 for staining.
BV510-anti-CD48 (HM48-1) BioLegend 103443 Store at 4 °C. Dilute 1:200 for staining.
BV711-anti-CD16/32 (93) BioLegend 101337 Store at 4 °C. Dilute 1:200 for staining.
Capillary tube  Shanghai Huake Labware Co. DC616297403604-100mm/0.5mm
Cell strainer CORNING 352340
Ethanol GENERAL-REAGENT 01158566
Ethylenediamine tetraacetic acid (EDTA) solution Servicebio G1105
Ethylenediaminetetraacetic acid dipotassium salt dihydrate (EDTA-K2) Solarbio E8651
FITC-anti-CD45.2 (104) BioLegend 109806 Store at 4 °C. Dilute 1:200 for staining.
Flowjo Becton, Dickinson & Company A flow cytometry.
Gelatin sponge Jiangxi Xiangen Co. Use under sterile conditions.
HBSS without Ca2+ and Mg2+ Gibco 14170112 HBSS without Ca2+ and Mg2+ can prevent cell aggregation.
Hematology analyzer Sysmex pocH-100i Diff
iodine swabs Xiangtan Mulan Biological Technology Co., Ltd. 01011 To prevent the infection after operation.
Isoflurane RWD R510-22-10  To avoid adverse effects of anesthesia waste gases on the environment and laboratory personnel, a gas recovery system should be used in conjunction.
Kraft paper absorbent paper
LIVE/DEAD Fixable Near IR Dead Cell Staining Kit(used in 3.4.5) Thermo Fisher Scientific L34962 A live/dead staining kit. Store at -20 °C. Dissolve in 50 μL of DMSO for working solution.
lubricating vet ointment Pfizer To prevent dryness and counteract the ocular irritations caused by isoflurane.
Neutral balsam Solarbio G8590
nylon filter Shanghai Shangshai Wire Mesh Manufacturing Co., Ltd. Used for cell filtration.
Paraffin liquid Macklin P815706
Paraformaldehyde (PFA) solution Servicebio G1101 Immersion fixation is used for routine animal tissues. The volume of fixative used is generally 10-20 times the tissue volume, and fixation at room temperature for 24 hours is sufficient.
PE-anti-CD45.1 (A20) BioLegend 110708 Store at 4 °C. Dilute 1:200 for staining.
PE-CF594-anti-CD135 (A2F10.1) BD Biosciences 562537 Store at 4 °C. Dilute 1:200 for staining.
PE-Cy5-anti-c-kit (2B8) BD Biosciences 105809 Store at 4 °C. Dilute 1:200 for staining.
PE-Cy7-anti-B220 (RA3-6B2) BioLegend 103222 Store at 4 °C. Dilute 1:200 for staining.
PE-Cy7-anti-CD150 (TC15-12F12.2) BioLegend 115914 Store at 4 °C. Dilute 1:200 for staining.
PE-Dazzle594-anti-CD4 (GK1.5) BioLegend 100456 Store at 4 °C. Dilute 1:200 for staining.
Pentobarbital sodium salt Sigma-Aldrich 57-33-0 Prepare for use at a concentration of 1% (w/v).
PerCp-Cy5.5-anti-CD8a (53-6.7) BioLegend 100734 Store at 4 °C. Dilute 1:200 for staining.
PerCp-Cy5.5-anti-lineage cocktail BD Biosciences 561317 Store at 4 °C. Dilute 1:10  for staining.
Red blood cell lysis buffer Beyotime C3702 Store at 4 °C. Use in clean bench.
rhBMP-2 Shanghai Rebone Biomaterials Co. The concentration of rhBMP-2 in the stock solution is 1.0 mg/mL.
Staining buffer BioLegend 420201 Store at 4 °C.
Xylene GENERAL-REAGENT 01018114
Zombie UV Fixable Viability Kit (used in 6.2.5) BioLegend 423108 A live/dead staining kit. For reconstitution, bring the kit to room temperature; add 100 µL of DMSO to one vial of Zombie UV dye until fully dissolved. 

Riferimenti

  1. Copelan, E. A. Hematopoietic stem-cell transplantation. New England Journal of Medicine. 354 (17), 1813-1826 (2006).
  2. Vittayawacharin, P., et al. Autologous hematopoietic stem cell transplantation for a patient with multiple autoimmune diseases. American Journal of Hematology. 98 (10), 1659-1662 (2023).
  3. Xu, L. -. P., et al. Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group. Bone Marrow Transplantation. 56 (12), 2940-2947 (2021).
  4. Gratwohl, A., et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 303 (16), 1617-1624 (2010).
  5. Sakurai, M., et al. Chemically defined cytokine-free expansion of human haematopoietic stem cells. Nature. 615 (7950), 127-133 (2023).
  6. Pineault, N., Abu-Khader, A. Advances in umbilical cord blood stem cell expansion and clinical translation. Experimental Hematology. 43 (7), 498-513 (2015).
  7. Liang, G., Liu, F. Long-term expansion of human hematopoietic stem cells. Cell Regeneration. 12 (1), 18 (2023).
  8. Wilkinson, A. C., Igarashi, K. J., Nakauchi, H. Haematopoietic stem cell self-renewal in vivo and ex vivo. Nature Reviews Genetics. 21 (9), 541-554 (2020).
  9. Kumar, S., Geiger, H. HSC niche biology and HSC expansion ex vivo. Trends in Molecular Medicine. 23 (9), 799-819 (2017).
  10. Dai, K., et al. A BMP-2-triggered in vivo osteo-organoid for cell therapy. Science Advances. 9 (1), 1541 (2023).
  11. Dai, K., Zhang, W., Deng, S., Wang, J., Liu, C. Sulfated polysaccharide regulates the homing of HSPCs in a BMP-2-triggered in vivo osteo-organoid. Advanced Science. 10 (24), e2301592 (2023).
  12. Alexander, T., Greco, R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation. 57 (7), 1055-1062 (2022).
  13. Ding, L., et al. Infusion of haploidentical HSCs combined with allogenic MSCs for the treatment of ALL patients. Bone Marrow Transplantation. 57 (7), 1086-1094 (2022).
  14. Sharrack, B., et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). Bone Marrow Transplantation. 55 (2), 283-306 (2020).
  15. Nelson, M. R., Roy, K. Bone-marrow mimicking biomaterial niches for studying hematopoietic stem and progenitor cells. J Mater Chem B. 4 (20), 3490-3503 (2016).
This article has been published
Video Coming Soon
Keep me updated:

.

Citazione di questo articolo
Zhang, W., Wei, X., Wang, Q., Dai, K., Wang, J., Liu, C. In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells. J. Vis. Exp. (204), e66026, doi:10.3791/66026 (2024).

View Video